Dr Newhouse is a Pulmonologist and Clinical Professor of Medicine, McMaster Faculty of Health Sciences, Hamilton, ON Canada.
He has an MD from Queen’s University, Kingston ON (1959), an MSc in Experimental Medicine from McGill University in Montreal PQ (1964) where he did his residency and a research fellowship in the Cardio-Pulmonary Division with Drs M.McGregor and M.Becklake (1960-64). His main research interest at that time was in lung mechanics related to the mechanisms underlying the increased oxygen cost and work of breathing during marked voluntary hyperventilation causing marked hypocapnea.
In 1972 he was named a Fellow of the Royal College of Physicians of Canada, and in 1975 a Fellowof the American College of Physicians. He became a Fellow of the College of Chest Physicians in 1980.
In 1964 he moved to Hamilton as Founding Director of the Pulmonary Division and Pulmonary Function Laboratory at St Joseph’s Hospital and in 1966 established the Medical Aerosol Research Laboratory there. His group was the first to publish studies on the distribution of ventilation, perfusion, aerosol deposition and clearance in man by Gamma Scintigraphy using radio-labeled aerosols and Xenon 135. This led to the use of inhaled aerosols instead of radioactive gases for ventilation/perfusion studies in pulmonary embolism. Over the next 25 years, with a number of post doctoral associates and research fellows, studies were carried out on the effect of air pollutants and exercise on mucus clearance from the airways, on pulmonary aerosol deposition and clearance in health and disease and on the effect of various medications on lung function and mucus clearance. He also undertook studies of normal and abnormal ciliary beat frequency and first described Primary Ciliary Dyskinesia (previously called “Immotile Cilia Syndrome”). Between 1966 and 1969 he assisted in the establishment of the McMaster Faculty of Health Sciences and in 1973 became Founding Director of the Firestone Regional Chest and Allergy Unit that subsequently developed into the present Firestone Institute for Respiratory Health (FIRH). He practiced clinical pulmonology, taught medical students and residents and supervised research fellows and post doctoral associates until he went to California as Director of Medical Affairs at Inhale (subsequently Nektar) Therapeutic Systems (1998-2005). During that time he was also Visiting Professor at the Stanford Faculty of Medicine in Palo Alto.
With numerous colleagues, residents and research fellows he has published over 150 original studies and numerous review articles, has co-edited books and contributed book chapters in clinical pulmonology and research. He has delivered several hundred invited lectures at academic centers and international conferences in many countries around the world.
His clinical interests have been mainly in asthma, COPD, cystic fibrosis and in simplifying and improving the MDI-based aerosol therapy of asthma and COPD by means of aerosol holding chambers. This resulted in the invention and development of the AeroChamber© a pocketable device that improves MDI-generated aerosol therapy compliance, reduces adverse upper respiratory tract and systemic adverse effects of corticosteroids and has largely replaced wet nebulization for treating asthma and COPD in infants and toddlers, adults ,the aged, and patients on ventilators (even horses with asthma) in over 100 countries. In Cystic Fibrosis (CF) he studied the benefit of various modalities of physical therapy and exercise on mucociliary and cough clearance of secretions and the benefit of inhaled vs IV antibiotic therapy with aminoglycosides for controlling Pseudomonas aeruginosa infection and improving longevity and quality of life in this disease.
He has also had a major interest in airway ciliary structure and function and in mucociliary transport in health and disease. He has also studied the effect of various drugs, air pollutants, exercise and chest physiotherapy on mucociliary transport and has studied mucus clearance in CF using various therapeutic modalities.
He has been on the editorial board and a reviewer for several major medical and pulmonary journals.
He was President of the International Society for Aerosols in Medicine from 1965-7.
He holds several patents in the area of aerosol delivery devices and is now mainly involved in research into new and improved concepts in pulmonary and systemic aerosol therapy and development of advanced delivery systems.
He is currently Chief Medical officer of a start-up Respiratory Co., InspiRx Pharmaceuticals and is developing innovative aerosol delivery systems particularly for the pediatric market.
He has a variety of non medical/scientific interests including bronze and welded sculpture, acrylic and oil painting and sailing. He has 5 terrific adult children raised mainly by his wife, Carol and 14 amazing grandchildren that are a lot of fun and a joy to be with.